Secondary analysis of PAOLA-1 (806 patients with newly diagnosed advanced ovarian cancer): adding maintenance olaparib to bevacizumab made no clinically meaningful difference to global health-related quality of life vs placebo plus bevacizumab.
Secondary analysisn = 806
Joly et al. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)